Curosurf is a clinical treatment for pre-term infants – born before 37 weeks of gestational age – suffering from infant respiratory distress syndrome (RDS), a life-threatening condition of the lungs. Curosurf was developed by Tore Curstedt and Bengt Robertson. Curstedt’s solution relies on a phospholipid extract of natural porcine lungs with the chemical name poractant alfa. Administered through a breathing tube and inserted into the trachea, Curosurf coats infants’ lung alveoli and reduces surface tension, thereby preventing RDS.
For additional digital leasing and purchase options contact a media consultant at 800-257-5126 (press option 3) or firstname.lastname@example.org.
Length: 8 minutes
Copyright date: ©2016
Prices include public performance rights.
Not available to Home Video and Publisher customers.
Retail Alliances, Not Washington, W...
Healthcare Associated Infections /A...
Military Medicine: Beyond the Battl...
The Patient's Playbook
Whose Death Is It Anyway? Tough Cho...
James G. Fujimoto (US): High Resolu...
132 West 31st Street, 16th Floor
New York, NY 10001
P: 800.322.8755 F: 800.678.3633
Sign Up for Special Offers!
© Films Media Group. All rights reserved.